Progression-Free and Overall Survival for Concurrent Nivolumab With Standard Concurrent Chemoradiotherapy in Locally Advanced Stage IIIA-B NSCLC: Results From the European Thoracic Oncology Platform NICOLAS Phase II Trial (European Thoracic Oncology Platform 6-14)
S. Peters, E. Felip, U. Dafni, A. Tufman, M. Guckenberger, R. Alvarez, E. Nadal, A. Becker, H. Vees, M. Pless, A. Martinez-Marti, M. Lambrecht, N. Andratschke, Z. Tsourti, A.C. Piguet, H. Roschitzki-Voser, A. Gasca-Ruchti, J. Vansteenkiste, R.A. Stahel*, D. De Ruysscher
Research output: Contribution to journal › Article › Academic › peer-review
Fingerprint
Dive into the research topics of 'Progression-Free and Overall Survival for Concurrent Nivolumab With Standard Concurrent Chemoradiotherapy in Locally Advanced Stage IIIA-B NSCLC: Results From the European Thoracic Oncology Platform NICOLAS Phase II Trial (European Thoracic Oncology Platform 6-14)'. Together they form a unique fingerprint.